IN2015DN01018A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01018A
IN2015DN01018A IN1018DEN2015A IN2015DN01018A IN 2015DN01018 A IN2015DN01018 A IN 2015DN01018A IN 1018DEN2015 A IN1018DEN2015 A IN 1018DEN2015A IN 2015DN01018 A IN2015DN01018 A IN 2015DN01018A
Authority
IN
India
Prior art keywords
acetoxy
propoxy
diphenyl
alkyl
methyl
Prior art date
Application number
Other languages
English (en)
Inventor
Smith Kathleen E Clarence
Thomas N Chase
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of IN2015DN01018A publication Critical patent/IN2015DN01018A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
IN1018DEN2015 2012-08-09 2013-07-30 IN2015DN01018A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681415P 2012-08-09 2012-08-09
PCT/US2013/052626 WO2014025569A1 (en) 2012-08-09 2013-07-30 Piperidinium quaternary salts

Publications (1)

Publication Number Publication Date
IN2015DN01018A true IN2015DN01018A (enExample) 2015-06-26

Family

ID=50068488

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1018DEN2015 IN2015DN01018A (enExample) 2012-08-09 2013-07-30

Country Status (14)

Country Link
US (1) US9896416B2 (enExample)
EP (1) EP2882711B1 (enExample)
JP (1) JP6345665B2 (enExample)
KR (2) KR20150040355A (enExample)
CN (2) CN108658842A (enExample)
AU (1) AU2013300009B2 (enExample)
BR (1) BR112015002832B1 (enExample)
CA (1) CA2881182C (enExample)
EA (1) EA029678B9 (enExample)
HK (1) HK1211572A1 (enExample)
IL (1) IL236996A0 (enExample)
IN (1) IN2015DN01018A (enExample)
MX (1) MX356386B (enExample)
WO (1) WO2014025569A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265128A4 (en) 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
EP4354912A3 (en) 2019-08-22 2024-04-24 Ofinno, LLC Policy control for multiple accesses
CN117018194B (zh) * 2023-07-26 2026-04-17 同济大学 毒蕈碱型受体5型受体拮抗剂的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD106643A1 (enExample) * 1973-07-12 1974-06-20
CN1285348A (zh) 1999-08-20 2001-02-28 广东康美药业股份有限公司 盐酸丙哌维林合成工艺
DE10129832A1 (de) * 2001-06-17 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
KR100500760B1 (ko) 2003-07-22 2005-07-14 동방에프티엘 주식회사 염산 프로피베린의 제조방법
KR100510788B1 (ko) 2003-07-22 2005-08-26 동방에프티엘 주식회사 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
CA2618933C (en) * 2005-08-12 2016-09-20 Dietmar Plenz Neuronal avalanche assay
CN1951938A (zh) * 2005-10-21 2007-04-25 刘丽娅 戊乙奎醚季铵盐及其衍生物
SE0600876L (sv) 2006-04-20 2007-10-21 Sandvik Intellectual Property Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form
CN101490003A (zh) 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
EP2013172A4 (en) 2006-04-24 2010-08-04 Astrazeneca Ab NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE
KR20120023059A (ko) * 2010-03-15 2012-03-12 라마크리시나 라메샤 안다가 프로피베린 염산염의 합성
KR101149821B1 (ko) 2010-04-05 2012-05-24 하나제약 주식회사 디페닐아세테이트 유도체의 새로운 제조방법
CN102218063B (zh) 2011-04-12 2013-03-13 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
AU2013312749B2 (en) * 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods

Also Published As

Publication number Publication date
EP2882711B1 (en) 2017-10-25
US9896416B2 (en) 2018-02-20
JP2015524469A (ja) 2015-08-24
MX2015001769A (es) 2015-05-08
EP2882711A4 (en) 2016-02-10
EA029678B9 (ru) 2018-07-31
JP6345665B2 (ja) 2018-06-20
HK1211572A1 (en) 2016-05-27
BR112015002832B1 (pt) 2022-08-16
AU2013300009A1 (en) 2015-02-26
AU2013300009B2 (en) 2017-06-15
US20150203452A1 (en) 2015-07-23
EP2882711A1 (en) 2015-06-17
BR112015002832A2 (enExample) 2017-07-04
CA2881182A1 (en) 2014-02-13
CN108658842A (zh) 2018-10-16
WO2014025569A1 (en) 2014-02-13
MX356386B (es) 2018-05-28
EA029678B1 (ru) 2018-04-30
KR20150040355A (ko) 2015-04-14
IL236996A0 (en) 2015-03-31
KR102240999B1 (ko) 2021-04-15
CA2881182C (en) 2021-01-26
CN104603108A (zh) 2015-05-06
KR20200022522A (ko) 2020-03-03
EA201500209A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MX2014011217A (es) Moduladores del receptor de estrogeno y sus usos.
EP4249055A3 (en) Tofacitinib oral sustained release dosage forms
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
IL221952A (en) Annotations 2, 3-Dihydro-1h - Indene-1-Il-7,2- Diazaspiro [5.3] Noonan and Pharmaceuticals Containing Them
MX2015008069A (es) Conjunto de envasado para dispositivos de administracion de farmacos.
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
HK1213779A1 (zh) 用於立即和延长释放的组合物
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
PH12014502856B1 (en) Solid pharmaceutical preparation containing levothyroxine
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
MY183068A (en) Pharmaceutical formulation comprising antibody
PH12015501115B1 (en) Learning and memory improver
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
IL246298A0 (en) History of piperidine, their preparation and pharmaceutical preparations containing them
MX356386B (es) Sales cuaternarias de piperidinio.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EP2807158A4 (en) (1R, 4R) 7-OXO-2-AZABICYCLO [2.2.2] OCT-5-EN AND DERIVATIVES THEREOF
WO2015022560A8 (en) Stable pharmaceutical composition containing bisoprolol and ramipril
IN2015DN02999A (enExample)
EP3091013A4 (en) 1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof
SI2953617T1 (sl) Farmacevtski sestavki, ki vključujejo nizkoodmerna zdravila
NZ702849A (en) Genotype- or phenotype-based drug formulation
WO2017004172A8 (en) Total synthesis of shishijimicin a and analogs thereof
WO2014122671A3 (en) Solid oral compositions of saxagliptin